Biology follows physical laws.

The question has never been whether those laws exist. The question is whether we have had the right tools to find them.

Consider how every major law of nature was uncovered. Archimedes needed an object he could systematically vary in size and shape, immersing it in water, observing what changed and what didn’t. 

From one probe, systematically varied, to one universal law: the upward buoyant force exerted on a body immersed in a fluid is equal to the weight of the fluid that the body displaces. 

From that equation came the ability to predict, from an object’s physical properties and the density of the fluid it enters, the exact upward force it will experience and whether it will float.

Every major technological breakthrough of the last century traces back to the same sequence: observe nature, write it in mathematics, build from it relentlessly.

Einstein, Turing, Kilby, Noyce did not stumble onto relativity, computation, or the transistor. They derived them. From heterogeneous catalysis to integrated circuits to the internet, the century was an engineering consequence of rules that had been found, named, and understood. 

Biology hasn’t had its equivalent. Not because the laws don’t exist, but because we haven’t had the right probe.

To find a law, you need a tool that can be varied systematically.

In materials science, we can do this with inorganic compounds: take a crystalline structure and change its size, its charge, its ionic composition, one variable at a time, and observe what happens. 

This is not possible with organic molecules. Change the composition of an organic molecule and you have a different molecule. You cannot independently vary its charge, size, and geometry while keeping everything else constant. You make one observation per compound and stop.

This is why immunology has remained, fundamentally, trial and error. We have extraordinary probes for other questions in biology: gene sequencing, CRISPR, proteomics. 

But for immune modulation, the tools we use are organic, be it antibodies, small molecules, peptides, or nucleic acids. You can only catalogue observations from fixed probes, not derive design rules.

AI models trained on data of questionable quality, producing outputs we cannot reverse-engineer, won’t help uncover laws. Even if a model yields a correct prediction, you cannot reverse-engineer how it reached the answer. Pattern matching is not the same as understanding.

If you can’t interrogate a system, you can’t comprehend it. If you can’t understand it, you can’t engineer it.

In 2014, researchers at Oxford¹ took a class of inorganic crystalline materials and systematically varied their physicochemical properties – composition, ionic radius, interlayer spacing, electrical charge. They measured the immune responses each material provoked. 

Every measured immune response correlated with just three physicochemical variables, conforming to a simple linear equation. The model then predicted, in advance, the responses of newly synthesised materials it had never seen. Accurately. 

That paper is the founding observation of Iuvantium. It was the first glimpse of a design rule for immunobiology: the first equation showing that immune responses can be predicted from physicochemical properties of inorganic materials. 

Iuvantium was founded on the conviction that inorganic nanoparticles are the systematic probe that immunology has been missing.

This is not a foreign intervention. Before DNA, before cells, before proteins, there were minerals. The very reactions that made life possible were catalysed by inorganic chemistry. Oxygen in our blood is transported bound to iron. Ion channels govern cellular excitability and communication. Trace metals catalyse nearly every major metabolic pathway.

The immune system is no different. Zinc is critical for T-cell development. Iron availability affects macrophage polarization. Magnesium regulates inflammasome activation. The NLRP3 inflammasome, one of the most important danger-sensing systems, responds to crystalline materials. 

iPrISM is iuvantium’s inorganic immunology platform. Functional inorganic nanoparticles with precisely controlled physicochemical properties: composition, crystal structure, surface chemistry, size, and charge – each independently tunable. 

Unlike organic therapeutics, which derive activity from molecular recognition, iPrISM materials exert immune control through their physicochemical identity. We can vary one parameter while holding others constant, observe what changes, and begin to derive rules.

Organic chemistry has four dominant elements. The periodic table has 118. That is the design space Iuvantium is opening. 

We systematically interrogate the immune system using these materials as probes. We map the relationship between material structure and immune phenotype across species and genetically diverse populations. Then we reverse engineer the precise immune response needed back into the material. The probe that decodes the system becomes the drug that treats it.

Our early data suggest something profound: that certain physicochemical properties drive immune control that transcends individual biological variation. That there are design rules for immunobiology, encoded in the language of inorganic chemistry.

From laws to medicines.

We are taking the same approach that cracked catalysis: systematic interrogation, precise variation of physicochemical properties, a proprietary map between material properties and immune phenotype. Each experiment adds to that map, and machine learning extracts from it what human analysis alone cannot. Over time it becomes something no one else has: a foundation model of immune behaviour, built from first principles.

Next-generation adjuvants are the de-risked entry point. Beyond them, a pipeline of novel nanoscale immune modulators across infectious disease, oncology, and autoimmune disease, tailored to genomics, age, and immunological history. Prophylactic and therapeutic approaches designed from first principles, for everyone.

If we are right, precision immunology finally earns its name.

If we are right, and our early results suggest we are, we can engineer immune responses the way we engineer catalysts, semiconductors, and rocket engines: with mathematical precision and predictable outcomes.

We control how the immune system responds, not just what it responds to. We encode any desired immune phenotype, rationally, intentionally, reproducibly, across species and genetically diverse populations.

That is what it means to turn immunology into an engineering discipline.